Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.

Learn more Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer ...

Big Pharma is pouring money into tech-devised treatments, but the verdict is out on whether they’ll actually work.

Quotient Sciences today announces the successful initiation of a clinical study evaluating a novel drug product developed ...

In this week’s edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure’s $7 ...

Artificial intelligence is shifting formulation development from empirical trial-and-error to predictive, data-driven design ...

The FDA proposes reducing animal testing for some cancer drugs as part of an effort to speed up R&D timelines with rodent-only trials in some cases. Read more here.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the Thermo Scientific™ Orbitrap™ Tribrid™ Apex and Thermo Scientific™ Orbitrap™ Excedion™ mass ...

Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...

There has been much discussion recently about how artificial intelligence and machine learning (AI/ML) will revolutionize pharmaceutical research. Substantial progress has been made in the discovery ...